Corpus Intelligence IC Memo — NORTH CANYON MEDICAL CENTER 2026-04-26 04:04 UTC
IC Memo — NORTH CANYON MEDICAL CENTER
Investment Committee Memorandum | ID | 16 beds | Grade C | EBITDA uplift $4.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NORTH CANYON MEDICAL CENTER

CCN 131302 | GOODING, ID | 16 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NORTH CANYON MEDICAL CENTER is a 16-bed rural/critical access in GOODING, ID with $53.7M in net patient revenue and a 4.3% operating margin. The hospital serves a payer mix of 51.4% Medicare, 5.8% Medicaid, and 42.8% commercial.

Thesis: Turnaround. Our ML models identify $4.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 4.3% to 11.7% (+736bps).

Net Revenue HCRIS$53.7M
Current EBITDA COMPUTED$2.3M
Operating Margin COMPUTED4.3%
Occupancy HCRIS26.7%
Revenue / Bed COMPUTED$3.4M
Net-to-Gross HCRIS57.1%
Distress Probability ML54.5%

2. Market Context & Competitive Position

51
ID Hospitals
-3.5%
State Median Margin
29
Comparable Hospitals

ID has 51 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 4.3% places it above the state median. Among 29 size-comparable peers (8-32 beds), the median margin is -5.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (8-32), prioritizing same-state peers. 29 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NORTH CANYON MEDICAL CENTER (Target)ID16$53.7M4.3%
BINGHAM MEMORIAL HOSPITALID25$164.8M-3.6%
NORTHWEST SPECIALTY HOSPITALID32$120.3M3.7%
TREASURE VALLEY HOSPITALID28$114.8M36.1%
ST. LUKES WOOD RIVER MEDICAL CID25$99.1M13.5%
GRITMAN MEDICAL CENTERID25$92.4M-6.4%
BONNER GENERAL HOSPITALID25$61.2M-7.6%
CASSIA REGIONAL HOSPITALID25$53.5M-9.9%
MINIDOKA MEMORIAL HOSPITALID23$48.0M-1.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$654K+122bp9mo
Clean Claim Rate88.0%96.0%$34K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.1M
Denial Rate Reduction
$1.1M
A/R Days Reduction
$654K
Clean Claim Rate
$34K
Total EBITDA Uplift$4.0M
Current EBITDA$2.3M
+ RCM Uplift+$4.0M
Pro Forma EBITDA$6.3M
Current Margin4.3%
Pro Forma Margin11.7%
WC Released (1x)$2.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.6M$55.0M15.31x72.6%
Base (11x exit)10.0x11.0x$3.6M$61.6M17.16x76.6%
Bull Case9.0x11.0x$3.2M$75.8M23.47x88.0%
Bull (12x exit)9.0x12.0x$3.2M$83.7M25.90x91.7%
Bear Case11.0x10.0x$3.9M$34.0M8.61x53.8%
Bear (11x exit)11.0x11.0x$3.9M$38.7M9.80x57.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 26.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 29 hospitals with 8-32 beds
  • Same-state prioritization (n=31)
  • Comp margins: P25=-9.9% / P50=-5.4% / P75=-1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.